EXPLORER-HCM: CAMZYOS (mavacamten) significantly improved symptom control (NYHA class) and exercise capacity (pVO2) vs placebo at Week 301,2
Primary endpoint
Percentage of patients achieving the primary composite endpoint* at Week 301,2
Treatment difference, 19.4%; 95% CI: 8.67 to 30.13; p=0.0005
Adapted from Olivotto I et al. 2020.2
*Primary composite endpoint defined as a ≥1.5 mL/kg/min increase in pVO2 and ≥1 NYHA class improvement or a ≥3.0 mL/kg/min increase in pVO2 and no worsening of
NYHA class.1,2
†96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
~2x
as many patients achieved the primary composite
endpoint with CAMZYOS vs placebo at Week 301,2
CAMZYOS consistently improved symptom control and exercise capacity across all analysed subgroups vs placebo2
Treatment effect on patients meeting the primary composite endpoint by subgroup, n (%)
Adapted from Olivotto I et al. 2020.2
The dashed vertical line (overall effect) represents the between-treatment group difference in the overall study cohort (19%).2
*96% of patients in the CAMZYOS treatment arm received background therapy with beta blocker or calcium channel blocker (76% [94/123] and 20% [25/123], respectively) vs 87% in the placebo arm (74% [95/128] and 13% [17/128], respectively).1,2
Explore additional efficacy data
Please refer to the CAMZYOS Summary of Product Characteristics for further information on dosing, initiation and safety.
BB, beta blocker; CI, confidence interval; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; pVO2, peak oxygen consumption; SoC, standard of care.
